Status:
TERMINATED
MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
55+ years
Phase:
PHASE2
Brief Summary
MK0952 is a phosphodiesterase type IV (PDE4) inhibitor in development for improvement of cognitive impairment in mild-to-moderate Alzheimer's disease.
Eligibility Criteria
Inclusion
- Male or females
- Age \>/= 55 years, With mild-to-moderate AD, with MMSE between 18 and 26, inclusive, MHIS score \</= 4, Global CDR score of 1 or 2
- Who have a reliable informant/caregiver to accompany patient to all clinic visits
- If using a symptomatic AD treatments, patients must be on stable dose for \>/= 6 months
Exclusion
- Patients must not be living in nursing home or skilled nursing facility
- Patients must not have current evidence and/or history of Crohn's disease, ulcerative colitis, proctitis, GI bleeding, mesenteric arteritis
- Patients must not have current evidence and/or history of poorly-controlled hypertension, clinically significant cardiac arrhythmia, angina, or CHF
- Patients must not have current evidence and/or history of a psychotic disorder or major untreated depressive disorder
- Patients must not have current evidence and/or history of stroke or multiple lacunar infarcts, or neurological or neurodegenerative disorder (other than AD)
- Various concomitant therapy restrictions
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2007
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00362024
Start Date
November 1 2006
End Date
November 1 2007
Last Update
May 16 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.